Radar · Diabetes in California
Best Diabetes Companies in California, United States
The 110 best Diabetes companies in California, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Kriya Therapeutics.
By Riya SenguptaFinancials
110companies tracked
$4.2Bdisclosed funding
0unicorns
60have raised
Ranked: Best Diabetes companies in California
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Kriya Therapeutics Developer of therapeutic solutions for the treatment of diabetes 53Funding top 16%News top 24%Moat top 31%Growth top 43% All 8 signals ▾Fundingtop 16% Newstop 24% Moattop 31% Growthtop 43% Markettop 44% Talenttop 50% Globalbottom 37% Techbottom 32% Funding: Raised $618M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) News: 5 BI events in 12 mo (of 16 tracked, 3 types) · 3 high-value events (IPO/M&A/funding/contracts) in 12 mo rank vs industry peers · Fliar Intelligence Index 53/100 | $618M | 10 mo ago | 159 | Shankar Ramaswamy Co-Founder & CEO | Series D | — | — |
| 2 | Carmot Developer of disease-modifying therapies to treat metabolic diseases | $401M | 36 mo ago | 50 | Heather Turner CEO | Acquired | — | — |
| 3 | ViaCyte Developer of cell therapy for the treatment of diabetes | $389M | 60 mo ago | 126 | — | Acquired | 582 patents Scalable stem cell manufacturing and encapsulated cell delivery devices for regenerative therapies | — |
| 4 | Intuity Medical All-in-one blood glucose monitoring system | $258M | 84 mo ago | 131 | — | Series F | 237 patents Point‑of‑care fluid sampling and analyte measurement devices for medical diagnostics | — |
| 5 | Livongo Provider of smart devices for diabetes management for patients and doctors | $237M | 72 mo ago | 163 | — | Acquired | — | — |
| 6 | OptiScan Biomedical Developer of a continuous monitoring system for use in the surgical intensive care unit (SICU) | $220M | 87 mo ago | 67 | Peter Rule CEO | Deadpooled | 289 patents Point‑of‑care fluid analyzers for glucose and biomarker measurement using disposable cassettes | — |
| 7 | Bigfoot Biomedical Developer of a closed-loop automated insulin delivery system | $215M | 63 mo ago | 133 | — | Acquired | 631 patents Automated insulin delivery and diabetes management devices and monitoring systems | — |
| 8 | Structure Developer of oral small molecule drugs for chronic diseases | $191M | 46 mo ago | 93 93 → 232 (+149%) | — | Public | — | — |
| 9 | Pelikan Technologies Top kimono buying sites comparison, reviews, and rankings | $183M | 208 mo ago | — | Dirk Boecker CEO | Deadpooled | 232 patents Point‑of‑care blood sampling and micro‑injection devices for minimally invasive diagnostics | — |
| 10 | Biolinq Provider of a wearable biosensor platform for diabetes monitoring 67Innovation top 13%Funding top 17%Patents top 17%Moat top 26% All 10 signals ▾Innovationtop 13% Fundingtop 17% Patentstop 17% Moattop 26% Talenttop 38% Growthtop 45% Marketbottom 45% Globalbottom 43% Techbottom 39% Newsbottom 18% Innovation: 189 patents (top 11% of patent-holders) · 161 filings since 2022 vs 28 in 2017-21 Funding: Raised $175M across 15 rounds · 15 rounds over 12 yrs (1.2/yr) rank vs industry peers · Fliar Intelligence Index 67/100 | $175M | 15 mo ago | 91 | Jared Tangney Co-Founder | Series C | 189 patents Minimally invasive microneedle-based continuous biosensing for interstitial fluid analytes | — |
| 11 | OrsoBio Developer of therapeutics for multiple metabolic diseases | $152M | 15 mo ago | 10 | — | Series B | 45 patents Small-molecule LXR modulators and ACMSD inhibitors for dyslipidemia and metabolic disease therapy | — |
| 12 | Zosano Pharma Developer of transdermal drug delivery systems for a broad range of therapeutic indications | $147M | 92 mo ago | 40 | — | Deadpooled | — | — |
| 13 | Tandem Diabetes Developer of devices for continuous glucose monitoring and manual insulin delivery | $101M | 73 mo ago | 1,922 1,922 → 2,202 (+15%) | Kim Blickenstaff President & CEO | Public | 698 patents Automated insulin delivery systems and smart infusion pump control technologies. | 1 job opening · 1 launch |
| 14 | Elcelyx Therapeutics Using the science of nutrient sensing for weight management and obesity-related metabolic disorders | $93M | 91 mo ago | 1 | Alain Baron Founder & CEO | Series E | 166 patents Formulating and delivering biguanide (metformin) drugs for glucose‑lowering metabolic therapies. | — |
| 15 | Perceive Bio Developer of therapeutics to treat diabetes and eye diseases | $78M | 41 mo ago | 12 | Anne Rubin President | Series B | — | — |
| 16 | C8 MediSensors Continuous glucose monitoring products | $70M | 168 mo ago | 25 | — | Deadpooled | 64 patents Advanced reflective optical spectroscopy and high‑NA imaging for biomedical analysis. | — |
| 17 | Tethys BioScience Biological Markers for Diagnoses | $53M | 191 mo ago | 81 | — | Deadpooled | 81 patents Biomarker discovery and diagnostic assay development for metabolic bone and diabetes diseases | — |
| 18 | Dexcom Provider of a wearable device for glucose monitoring | $53M | 74 mo ago | 9,600 9,600 → 8,782 (-9%) | Kevin Sayer CEO & President | Public | 4,656 patents Continuous glucose monitoring sensors, data transmission, and glycemic management software | — |
| 19 | Metronom Health Developer of continuous glucose monitoring systems for diabetes management | $49M | 65 mo ago | 69 | Roy Cosan CEO | Series B | 66 patents Wearable opto‑enzymatic analyte sensors with specialized skin‑adhesive attachment systems | — |
| 20 | GlySens Implantable Continuous glucose monitoring device | $47M | 72 mo ago | 29 | William Markle CEO | Late Stage | 70 patents Continuous implantable glucose monitoring with integrated insulin delivery error correction | — |
| 21 | Calyx Therapeutics Developer of small molecule therapeutics for Diabetes and Rheumatoid arthritis | $44M | 294 mo ago | — | Mark Schwartz CEO | Acquired | — | — |
| 22 | Tolerion Developer of therapeutics to treat autoimmune diseases | $43M | 76 mo ago | 12 | John Statham Founder | Deadpooled | 17 patents Stabilized DNA therapeutics and immunomodulatory treatments for type 1 diabetes | — |
| 23 | Signos Provider of a wearable device for blood glucose pattern monitoring 42Tech top 20%Funding top 25%Moat top 39%Customers top 44% All 10 signals ▾Techtop 20% Fundingtop 25% Moattop 39% Customerstop 44% Producttop 46% Talentbottom 49% Marketbottom 40% Globalbottom 36% Growthbottom 31% Newsbottom 22% Tech: 52 technologies across 6/8 capability areas · Cloud: Amazon Cloudfront, Amazon Web Services Funding: Raised $37.0M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 42/100 | $37M | 0 mo ago | 30 | Sharam Fouladgar-Mercer Co-Founder & CEO | Series B | — | — |
| 24 | Siren Provides smart socks for preventing diabetic foot ulcers 42Talent top 28%Funding top 29%Growth top 35%Product top 46% All 7 signals ▾Talenttop 28% Fundingtop 29% Growthtop 35% Producttop 46% Techbottom 45% Globalbottom 39% Marketbottom 25% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $30.9M across 8 rounds · 8 rounds over 11 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 42/100 | $31M | 17 mo ago | 22 | Henk Scholten Co-Founder & COO | Series B | — | — |
| 25 | Movano Health Developer of radio frequency-enabled health monitoring devices and wearable technology | $30M | 26 mo ago | 27 | John Mastrototaro CEO | Public | — | — |
| 26 | Metrika Tyumen real estate agency specializing in property sales and related services | $26M | 302 mo ago | 50 | — | Acquired | 50 patents Point‑of‑care fluidic diagnostic devices with cartridge‑based sample mixing and flow control | — |
| 27 | Sano Intelligence Provider of blood sugar monitoring wearable device | $24M | 101 mo ago | 13 | Raj Gokal Co-Founder | Acqui-Hired | 31 patents Wearable continuous biosensor devices for real-time body chemistry monitoring | — |
| 28 | Companion Medical Medtronic Diabetes: Innovative solutions for diabetes management and insulin delivery | $21M | 77 mo ago | — | Sean Saint CEO & President | Acquired | — | — |
| 29 | Modular Medical Developer of insulin pump designed for simplified diabetes management and care | $20M | 15 mo ago | — | Paul Diperna Founder | Public | — | — |
| 30 | MingSight Developer of therapeutics to treat cancer and ophthalmological diseases | $20M | 55 mo ago | 3 | Kai Zhang CEO | Series A | — | — |
| 31 | Paulex Bio Developer of therapeutics for diabetes treatment | $19M | 7 mo ago | — | Miguel Sanjuan CEO & Founder | Series B | — | — |
| 32 | ArKal Medical Minimally invasive continuous glucose monitoring system | $18M | 213 mo ago | 11 | — | Deadpooled | — | — |
| 33 | Surf Bio Developer of therapeutics for the treatment of multiple diseases | $16M | 25 mo ago | 4 | Jennifer Schneider Md Founder | Acquired | — | — |
| 34 | Laxmi Therapeutic Devices Develper of a wearable diagnostic device for continuous glucose monitoring | $14M | 22 mo ago | 38 38 → 30 (-21%) | Bill Antwerp Co-Founder | Series A | — | — |
| 35 | Freedom Meditech Environmental monitoring equipment and high-standard farmland equipment research, production, sales, and… | $13M | 133 mo ago | 1 | — | Series C | 26 patents Non‑invasive biomedical imaging of tissue biomechanics and AI‑driven diabetes diagnostics | — |
| 36 | Decision Diagnostics Manufactures Diabetes monitoring device | $12M | 150 mo ago | 6 | — | Funding Raised | — | — |
| 37 | Modulim Provider of non-invasive imaging devices for detection of diabetics foot ulcer | $12M | 90 mo ago | 14 14 → 9 (-36%) | David Cuccia Founder | Series B | — | — |
| 38 | Vivani Developer of a drug delivery medical device for diabetes | $8M | 14 mo ago | 37 37 → 36 (-3%) | Adam Mendelsohn Co-Founder & CEO | Public | — | 2 launchs |
| 39 | Renova Therapeutics Developer of gene therapies for congestive heart failure and type 2 diabetes | $8M | 22 mo ago | 7 | Jack Reich Chief Executive Officer | Series C | — | — |
| 40 | Islet Sciences US-based, early-stage biopharma developing interleukin 12 inhibitors for Diabetes treatment | $8M | 125 mo ago | 5 | Gary Blackburn CEO & President | Public | — | — |
| 41 | Seraphina Therapeutics US-based preclinical stage biopharma developing a lipid based therapeutic for cardiometabolic disease | $6M | 73 mo ago | 2 | Stephanie Watson Co-Founder & CEO | Series A | — | — |
| 42 | Modular Medical Developer of insulin pump for insulin delivery | $5M | 63 mo ago | 36 36 → 54 (+50%) | — | Series A | — | 2 job openings · 1 launch |
| 43 | Halo Biosciences Developer of therapies by editing extracellular matrix | $5M | 14 mo ago | 12 | Andy Wardle Co-Founder & Advisor | Funding Raised | — | — |
| 44 | PercuSense Minimally invasive devices for continuous monitoring of glucose, sepsis, and cancer | $5M | 72 mo ago | — | Brian Kannard CEO | Funding Raised | 77 patents Patents concentrated in health & consumer products | — |
| 45 | IMS Provider of a wearable smart sensor for glucose monitoring | $5M | 10 mo ago | 5 | Muhammad U Rahman Founder | Funding Raised | 72 patents Vehicle telematics and driver behavior analytics, including OBD, smartphone integration, and traffic alerts | — |
| 46 | Capillary Biomedical Provider of implants for continuous glucose monitoring | $3M | 68 mo ago | 1,922 | — | Acqui-Hired | 19 patents Subcutaneous insulin infusion devices with advanced insertion and delivery control mechanisms. | — |
| 47 | XOStem Developer of stem cells and bio-artificial organs for treating diabetes | $1M | 28 mo ago | 8 | John Sanderson Co-Founder & CEO | Seed | — | — |
| 48 | Isla technologies Developer of minimally invasive cell implant to treat type 1 diabetes | $1M | 39 mo ago | — | Sara Photiadis CEO | Seed | — | — |
| 49 | Metanoia Bio Provider of platform technology to prevent diabetes | $1M | 3 mo ago | 5 | Jake Mendelsohn Co-Founder | Seed | — | — |
| 50 | Dorian Therapeutics Developer of therapies for aging diseases | $150K | 13 mo ago | 9 | — | Acquired | — | 1 award |
Top 12 Diabetes companies in California
#1
Series B · San Francisco, California · founded 2020 · 30 employees$37Mraised▾
Series B · San Francisco, California · founded 2020 · 30 employees
Provider of a wearable device for blood glucose pattern monitoring. The company has developed an app-based platform that recommends meals and exercises for users based on the glucose pattern detected through the connected device. The app provides real-time glucose monitoring and glucose spike levels for different foods. Based on this, personalized fitness and nutrition plan can be developed.
Fliar Intelligence Index™ 42how this company ranks against its industry peers
Tech
top 20%Funding
top 25%Moat
top 39%Customers
top 44%Product
top 46%Talent
bottom 49%Tech: 52 technologies across 6/8 capability areas · Cloud: Amazon Cloudfront, Amazon Web Services · Devops: Envoy
Funding: Raised $37.0M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) · Last round Series B (May 2026)
Moat: Editorial + unicorn rating 7/10 · 9 curated direct competitors tracked
Audience (LinkedIn): 9k LinkedIn followers
Funding rounds
- Oct 2023Series B$20M
- Nov 2021Series A$13M
- Jan 2021Seed$4M
Founders & team
Investors
Cheyenne Ventures, Google Ventures, Dexcom Ventures, Samsung NEXT, Courtside Ventures, 1984 Ventures
Tech stack
AddshoppersAmazon CloudfrontAmazon Web ServicesCloudflareCloudflare Bot ManagementCore-Js
#2
Series D · Redwood City, California · founded 2012 · 159 employees$617.6Mraised▾
Series D · Redwood City, California · founded 2012 · 159 employees
Developer of therapeutic solutions for the treatment of diabetes. The company has developed AAV-based gene therapies for the treatment of type 1 and type 2 diabetes. Its drug candidate KT-A112 contains insulin and glucokinase proteins that help in treating Type 1 & Type 2 diabetes mellitus. It also provides KT-A522 with glucagon-like peptide (GLP-1) receptor agonist for the treatment of Type 2 diabetes, KT-A832 insulin growth factor that helps in treating diabetes mellitus.
Fliar Intelligence Index™ 53how this company ranks against its industry peers
Funding
top 16%News
top 24%Moat
top 31%Growth
top 43%Market
top 44%Talent
top 50%Funding: Raised $618M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) · Last round Series D (Jul 2025)
News: 5 BI events in 12 mo (of 16 tracked, 3 types) · 3 high-value events (IPO/M&A/funding/contracts) in 12 mo · Top themes: Funding, Leadership, Capital raise
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 10 curated direct competitors tracked
Funding rounds
- Jul 2025Series D$320.8M
- May 2022Series C$430M
- Jun 2021Series B$100M
- May 2020Series A$87.6M
Founders & team
Investors
QVT Family Office, Dexcel, Foresite Capital, Narya, Amplo, Asia Alpha
Tech stack
CloudflareGoogle AnalyticsJqueryJquery MigrateModernizrMysql
#3
Series C · San Diego, California · founded 2012 · 91 employees$175.1Mraised▾
Series C · San Diego, California · founded 2012 · 91 employees
Provider of a wearable biosensor platform for diabetes monitoring. It offers a wireless microsensor that enables users to understand their metabolism and blood glucose levels in real-time.
Fliar Intelligence Index™ 67how this company ranks against its industry peers
Innovation
top 13%Funding
top 17%Patents
top 17%Moat
top 26%Talent
top 38%Growth
top 45%Innovation: 189 patents (top 11% of patent-holders) · 161 filings since 2022 vs 28 in 2017-21 · Deep-tech classification: Tech Hardware
Funding: Raised $175M across 15 rounds · 15 rounds over 12 yrs (1.2/yr) · Last round Series C (Mar 2025)
Patents: 189 patents matched (strict assignee match) · 161 filings since 2022 vs 28 in 2017-21 · Latest publication 2026
Funding rounds
- Mar 2025Series C$100M
- Dec 2023Series B$59.1M
- Nov 2021Series B$100M
- Sep 2021Grant (prize money)$1.9M
Founders & team
Investors
M Ventures, Hikma Ventures, Three Leaf Ventures, LifeSci Venture Partners, GSVP, Alpha Wave Global
Tech stack
Google AnalyticsGreenhouseJqueryJsdelivrLottiefilesOpen Graph
#4
Series B · Palo Alto, California · founded 2021 · 10 employees$151.6Mraised▾
Series B · Palo Alto, California · founded 2021 · 10 employees
Developer of therapeutics for multiple metabolic diseases. It offer drug cangidates that target central pathways of energy metabolism which include ACC2 inhibitor TLC-3595 for type-2 diabetes, LXR inverse agonist TLC-2716 for Severe Dyslipidemias, Mitochondrial protonophore TLC-6740, and TLC-1235 for Lipodystrophies.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 3k LinkedIn followers
Funding rounds
- Feb 2025Series B$1.7M
- Feb 2025Grant (prize money)$2.3M
- Aug 2024Series B$67M
- Oct 2023Series A$84.6M
Investors
Longitude Capital, Enavate Sciences, Samsara BioCapital, NuevaBio, Lilly, Ascenta Capital
#5
Series B · San Diego, California · founded 2023$18.5Mraised▾
Series B · San Diego, California · founded 2023
Developer of therapeutics for diabetes treatment. It offers regeneration therapies for the treatment and prevention of Type-1 and Type-2 Diabetes.
Funding rounds
- Nov 2025Series B$18.5M
Founders & team
#6
Series B · San Francisco, California · founded 2015 · 22 employees$30.9Mraised▾
Series B · San Francisco, California · founded 2015 · 22 employees
Sirencare provides smart socks for preventing diabetic foot ulcers. The sock is embedded with a sensor that tracks foot temperature and issues related to inflammation. It comes with a companion app, that sends notifications to the user & doctor on signs of inflammation. To ensure accuracy, the user receives a new shipment of socks to replace the current supply every six months.
Fliar Intelligence Index™ 42how this company ranks against its industry peers
Talent
top 28%Funding
top 29%Growth
top 35%Product
top 46%Tech
bottom 45%Global
bottom 39%Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
Funding: Raised $30.9M across 8 rounds · 8 rounds over 11 yrs (0.7/yr) · Last round Series B (Jan 2025)
Growth: Fresh capital in last 24 mo
Audience (LinkedIn): 4k LinkedIn followers
Funding rounds
- Jan 2025Series B$9.5M
- Sep 2020Series B$9M
- May 2020Series B$11.8M
- 2018Series A$6.5M
Founders & team
Investors
Manta Ray Ventures, Mighty Capital, Portfolia, Khosla Ventures, DCM Ventures, Founders Fund
Tech stack
CloudflareCookiebotGoogle AnalyticsGoogle Font ApiGoogle Hosted LibrariesGoogle Workspace
#7
Seed · Los Angeles, California · founded 2020 · 5 employees$1.2Mraised▾
Seed · Los Angeles, California · founded 2020 · 5 employees
Provider of platform technology to prevent diabetes. It offers a conserved pathway for physiologically induced tissue regeneration that will restore beta-cell function and induce homeostatic cell fitness competition for the maintenance of functional beta-cell mass.
Funding rounds
- Mar 2026Seed$900K
- Jul 2024Grant (prize money)$295.3K
Founders & team
Investors
HHS, Healthspan Capital
#8
Funding Raised · Orange, California · founded 2015 · 5 employees$4.6Mraised▾
Funding Raised · Orange, California · founded 2015 · 5 employees
Integrated Medical Sensors provides a wearable smart sensor for glucose monitoring. The sensor is small in size and can be worn under one's clothing or as a standard smartwatch. The device can be paired with a mobile application to receive results on the user's smartphone.
Funding rounds
- Aug 2025Grant (prize money)$285K
- Jan 2025Grant (prize money)$350K
- Sep 2024Grant (prize money)$495.5K
- Sep 2023Grant (prize money)$350K
Founders & team
Investors
HHS
Tech stack
WordpressMysqlPhpBootstrapW3 Total CacheApache Http Server
#9
Public · San Diego, California · founded 2014$20Mraised▾
Public · San Diego, California · founded 2014
Developer of insulin pump designed for simplified diabetes management and care. The pump aims to remove complicated technology, facilitating a smooth transition from manual injections. It is designed to enable data sharing with healthcare teams. The device is intended to help manage diabetes more effectively.
Funding rounds
- Mar 2025Post IPO$12M
- 2024Post IPO$8M
Founders & team
Tech stack
CloudflareGoogle Font ApiGoogle Hosted LibrariesHstsHttp/3Jquery
#10
Acquired · Berkeley, California · founded 2008 · 50 employees$400.5Mraised▾
Acquired · Berkeley, California · founded 2008 · 50 employees
Developer of disease-modifying therapies to treat metabolic diseases. The company is pioneering a drug discovery platform, to identify novel incretin receptor signaling targets to develop a broad pipeline of therapeutics for metabolic diseases including obesity and diabetes. The company has three clinical candidates including CT-388, CT-868, and CT-996.
Funding rounds
- May 2023Series E$150M
- Jul 2022Series D$160.7M
- Sep 2020Series C$47M
- Jan 2018Series B$15M
Founders & team
Investors
Leader Ventures, RA Capital Management, Deep Track Capital, Willett Advisors, Horizons Ventures, The Column Group
#11
Public · Emeryville, California · founded 2009 · 37 employees$8.2Mraised▾
Public · Emeryville, California · founded 2009 · 37 employees
Developer of a drug delivery medical device for diabetes. It offers a lead candidate NPM-119 a GLP-1 receptor agonist which is a subdermal, exenatide drug implant to treat type 2 diabetes. It is based on NanoPortal platform technology which make extended-release therapeutic implants.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 1k LinkedIn followers
Activity: 2 product launches announced in 12 mo
Funding rounds
- Mar 2025Post IPO$8.2M
Founders & team
Tech stack
Animate.CssAosApache Http ServerBootstrapCdnjsCloudflare
#12
Funding Raised · Stanford, California · founded 2019 · 12 employees$5Mraised▾
Funding Raised · Stanford, California · founded 2019 · 12 employees
Developer of therapies by editing extracellular matrix. The lead product H01 is a small-molecule drug that inhibits the synthesis of hyaluronan and treats respiratory conditions like ARDS. Other therapeutic H02 also inhibits hyaluronan synthesis and is in development for lung, liver, diabetes, and metabolic diseases.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 536 LinkedIn followers
Funding rounds
- Mar 2025Grant (prize money)$3M
- May 2024Grant (prize money)$2M
Founders & team
Investors
HHS, QB3
Funding & investor landscape
$4.2Btotal disclosed funding
61companies funded
264disclosed rounds
0rounds last 90 days
Most active investors
Notable founders
Sharam Fouladgar-Mercer
Co-Founder & CEO · Signos
Shankar Ramaswamy
Co-Founder & CEO · Kriya Therapeutics
Roger Jeffs
Co-Founder · Kriya Therapeutics
Jared Tangney
Co-Founder · Biolinq
Richard Yang
CEO · Biolinq
Miguel Sanjuan
CEO & Founder · Paulex Bio
Francisco Leon
Co-Founder · Paulex Bio
Henk Scholten
Co-Founder & COO · Siren
Jie Fu
Co-Founder · Siren
Jake Mendelsohn
Co-Founder · Metanoia Bio
Brent Cohen
Chairman and Cofounder · Metanoia Bio
Muhammad U Rahman
Founder · IMS
Prism market signals · United States · country-scoped Prism corpus, 11,125,692 docs
Market landscape — 10 sub-themes by coverage
Share of Diabetes coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
How many Diabetes companies are there in California, United States?
Radar tracks 110 indexable Diabetes companies headquartered in California, United States that meet our profile-completeness bar.
What is the total funding raised by Diabetes companies in California, United States?
The Diabetes companies in California, United States on this list have raised a combined $4.2B in disclosed equity funding across 61 funded companies.
Which is the highest-funded Diabetes company in California, United States?
Kriya Therapeutics is the highest-funded Diabetes company in California, United States, with $617.6M in disclosed equity funding.
How many Diabetes companies in California, United States are funded?
61 of the 110 Diabetes companies in California, United States on this list have disclosed at least one equity funding round.
How many Diabetes unicorns are there in California, United States?
None of the Diabetes companies in California, United States on this list currently has a disclosed valuation of $1B or more.
Who are the top investors in California, United States Diabetes companies?
The most active investors in California, United States Diabetes companies on this list include HHS, BioBrit, T1D Fund, Hercules Capital, Delphi Ventures.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.